Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 18, 2022

Antitumor Activity of Lurbinectedin in Relapsed Ewing Sarcoma

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Clin. Cancer Res 2022 Apr 29;[EPub Ahead of Print], V Subbiah, I Brana, A Longhi, V Boni, JP Delord, A Awada, P Boudou-Rouquette, J Sarantopoulos, GI Shapiro, A Elias, R Ratan, C Fernandez, C Kahatt, M Cullell-Young, M Siguero, A Zeaiter, SP Chawla

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading